All In Biotech

Drug Trial Radar · NCT03416530

ONC201 in Pediatric H3 K27M Gliomas

ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas

Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

134

Actual

Start

Jan 25, 2018

Primary completion

Dec 31, 2022

Study completion May 24, 2023

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Oncoceutics, Inc.
First posted
Jan 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 1, open label, multicenter, 8-arm, dose escalation study of dordaviprone (ONC201) in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent/refractory H3 K27M-mutant gliomas. The primary endpoint of this study was to determine the recommended Phase 2 dose (RP2D) of dordaviprone (ONC201) in pediatric glioma patients as a single agent in combination with radiation.

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • Glioma, Malignant

Interventions

  • Dordaviprone (ONC201)Drug

    Dordaviprone is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2DTime frame: 28 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF, Benioff Children's Hospital

    San Francisco, California

  • Miami Cancer Institute

    Miami, Florida

  • Children's Healthcare of Atlanta, Emory University School of Medicine

    Atlanta, Georgia

  • University of Michigan Cancer Center

    Ann Arbor, Michigan

  • New York University

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.